
    
      A study of erdafitinib versus standard of care, consisting of chemotherapy (docetaxel or
      vinflunine) or anti-PD-(L) 1 agent pembrolizumab, in participants with advanced urothelial
      cancer and selected FGFR aberrations who have progressed on or after 1 or 2 prior treatments,
      at least 1 of which includes an anti-PD-(L) 1 agent (cohort 1) or 1 prior treatment not
      containing an anti-PD-(L) 1 agent (cohort 2). It will consist of screening, treatment phase
      (from randomization until disease progression, intolerable toxicity, withdrawal of consent or
      decision by investigator to discontinue treatment, post-treatment follow-up (from
      end-of-treatment to participants death, withdraws consent, lost to follow-up, or end of
      study, whichever comes first). Efficacy, pharmacokinetics, biomarkers, patient reported
      outcomes, medical resource utilization and safety will be assessed.
    
  